NextCell Pharma AB
65G
Company Profile
Business description
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Contact
Karolinska Institutet Science Park
Halsovagen 7
Huddinge14157
SWET: +46 87355595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
ASX iron ore player downgraded ahead of earnings
Rising costs and delayed production drive fair value cut for ASX iron ore player.
stocks
Global tensions drive profitability for ASX energy provider
Supply disruptions turbocharge refining profits and lift earnings forecasts for ASX energy share.
stocks
ASX energy share undervalued ahead of earnings
Pricing strength outweighs temporary production headwinds.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,354.80 | 9.10 | 0.10% |
| CAC 40 | 8,666.63 | 52.81 | 0.61% |
| DAX 40 | 26,202.35 | 201.04 | 0.77% |
| Dow JONES (US) | 54,085.88 | 907.47 | 1.71% |
| FTSE 100 | 10,879.38 | 21.68 | 0.20% |
| HKSE | 25,919.26 | 66.34 | 0.26% |
| NASDAQ | 26,584.99 | 671.10 | 2.59% |
| Nikkei 225 | 65,861.00 | 1,903.47 | 2.98% |
| NZX 50 Index | 13,917.81 | 14.35 | 0.10% |
| S&P 500 | 7,736.52 | 136.02 | 1.79% |
| S&P/ASX 200 | 9,176.00 | 0.50 | -0.01% |
| SSE Composite Index | 3,855.92 | 33.64 | 0.88% |